Structure Therapeutics Inc (GPCR)
41.75
+0.22
(+0.53%)
USD |
NASDAQ |
Sep 27, 16:00
41.65
-0.10
(-0.24%)
After-Hours: 20:00
Structure Therapeutics Research and Development Expense (Annual): 70.10M for Dec. 31, 2023
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 70.10M |
| December 31, 2022 | 36.19M |
| Date | Value |
|---|---|
| December 31, 2021 | 29.11M |
| December 31, 2020 | 12.36M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
12.36M
Minimum
2020
70.10M
Maximum
2023
36.94M
Average
32.65M
Median
Research and Development Expense (Annual) Benchmarks
| Viking Therapeutics Inc | 63.81M |
| Eli Lilly and Co | 9.313B |
| Novo Nordisk AS | 4.710B |
| Amgen Inc | 4.784B |
| Pfizer Inc | 10.68B |